Positive phase 3 data for Sanofi’s Dupixent
Research showed significant improvements in signs and symptoms of prurigo nodularis
Read More
Tag: Dupixent
Sanofi and Regeneron’s Dupixent shows consistent safety profile
Study involving children aged six to 11 years with moderate-to-severe asthma reveals positive data
Read More
Sanofi and Regeneron’s Dupixent shows positive results in phase 3 trial
Trial focusing on children with eosinophilic oesophagitis has met its primary endpoint
Read More
Dupixent hits all endpoints in prurigo nodularis trial
Dupixent significantly reduced itch and skin lesions compared to placebo in the investigational trial setting
Read More
Dupixent trial meets endpoints for childhood eczema
Sanofi/Regeneron biologic offers alternative to topical steroids
Read More
Sanofi, Regeneron’s Dupixent ‘rapidly’ improves lung function in children
Detailed results found Dupixent improved overall asthma control in children aged six to 11 years old
Read More
FDA to review Sanofi/Regeneron’s Dupixent in children with uncontrolled asthma
Sanofi is also planning an EU regulatory submission for Dupixent in the same indication
Read More
Dupixent approved in EU for atopic dermatitis in children
First biologic to be approved for children aged six to 11 years with condition
Read More
Sanofi’s Dupixent reduces severe asthma attacks in children
Biologic therapy hit primary and all key secondary endpoints in phase III
Read More
Sanofi unveils new data for Dupixent in children with dermatitis
Nearly three times as many children achieved clear or almost clear skin when treated with Dupixent and standard-of-care topical corticosteroids
Read More
Dupixent hits endpoints in paediatric trial
33% of patients who received Dupixent every four weeks achieved clear or almost clear skin.
Read More
FDA approves Dupixent, Darzalex, Soliris
Dupixent is the first and only biologic treatment for adults with chronic rhinosinusitis with nasal polyposis.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
